ACADIA Pharmaceuticals to present at JMP Securities Conference
The company focuses on the development and commercialization of medication candidates that would treat neural diseases.
Currently the company has three medication candidates to treat four conditions. One of these is Pimavanserin, which is currently in Phase II clinical trials for indications for schizophrenia and Alzheimer’s related psychosis. The medicine, known as NUPLAZID, has been approved by the U.S. for use to treat Parkinson’s disease-released psychosis.
The company’s andrenergic candidate for chronic pain is also in Phase II clinical trials, and it also has a muscarinic candidate for the treatment of glaucoma that is in the first phase of clinical trials.
The presentation will be available through a webcast at the company’s investors’ section of its website. It will also be made available on the website until July 5.
The presentation is scheduled to begin at 9 a.m. EDT on June 21.
ACADIA is focused on the development of medication to treat unmet medical needs for neurological diseases.